Microba Life Sciences Limited
Get $10 bonus on your first $100 deposit for MAP.AX
Get $10 bonus on your first $100 deposit for MAP.AX
Microba Life Sciences Limited (MAP.AX) Stock Competitors & Peer Comparison
See (MAP.AX) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MAP.AX | A$0.07 | -1.45% | 34.9M | -1.70 | -A$0.04 | N/A |
| SHL.AX | A$19.98 | -1.91% | 9.9B | 18.00 | A$1.11 | +5.41% |
| IDX.AX | A$2.25 | -3.02% | 839.1M | 56.25 | A$0.04 | +3.24% |
| ACL.AX | A$2.03 | -0.49% | 384.3M | 14.50 | A$0.14 | +6.28% |
| HLS.AX | A$0.52 | -5.45% | 377.6M | -0.68 | -A$0.76 | +122.07% |
| MVF.AX | A$0.66 | +0.00% | 257.2M | 16.50 | A$0.04 | +1.82% |
| LDX.AX | A$0.21 | -10.64% | 167.5M | -10.50 | -A$0.02 | N/A |
| PEB.AX | A$0.15 | +0.00% | 148.2M | -4.83 | -A$0.03 | N/A |
| RHY.AX | A$0.19 | -2.56% | 62.7M | -9.50 | -A$0.02 | N/A |
| CTE.AX | A$1.10 | -0.45% | 53.4M | 27.38 | A$0.04 | N/A |
Stock Comparison
MAP.AX vs SHL.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, SHL.AX has a market cap of 9.9B. Regarding current trading prices, MAP.AX is priced at A$0.07, while SHL.AX trades at A$19.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas SHL.AX's P/E ratio is 18.00. In terms of profitability, MAP.AX's ROE is -0.63%, compared to SHL.AX's ROE of +0.06%. Regarding short-term risk, MAP.AX is less volatile compared to SHL.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check SHL.AX's competition here
MAP.AX vs IDX.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, IDX.AX has a market cap of 839.1M. Regarding current trading prices, MAP.AX is priced at A$0.07, while IDX.AX trades at A$2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas IDX.AX's P/E ratio is 56.25. In terms of profitability, MAP.AX's ROE is -0.63%, compared to IDX.AX's ROE of +0.02%. Regarding short-term risk, MAP.AX is less volatile compared to IDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check IDX.AX's competition here
MAP.AX vs ACL.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, ACL.AX has a market cap of 384.3M. Regarding current trading prices, MAP.AX is priced at A$0.07, while ACL.AX trades at A$2.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas ACL.AX's P/E ratio is 14.50. In terms of profitability, MAP.AX's ROE is -0.63%, compared to ACL.AX's ROE of +0.16%. Regarding short-term risk, MAP.AX is more volatile compared to ACL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check ACL.AX's competition here
MAP.AX vs HLS.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, HLS.AX has a market cap of 377.6M. Regarding current trading prices, MAP.AX is priced at A$0.07, while HLS.AX trades at A$0.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas HLS.AX's P/E ratio is -0.68. In terms of profitability, MAP.AX's ROE is -0.63%, compared to HLS.AX's ROE of -0.29%. Regarding short-term risk, MAP.AX is less volatile compared to HLS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check HLS.AX's competition here
MAP.AX vs MVF.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, MVF.AX has a market cap of 257.2M. Regarding current trading prices, MAP.AX is priced at A$0.07, while MVF.AX trades at A$0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas MVF.AX's P/E ratio is 16.50. In terms of profitability, MAP.AX's ROE is -0.63%, compared to MVF.AX's ROE of +0.06%. Regarding short-term risk, MAP.AX is more volatile compared to MVF.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check MVF.AX's competition here
MAP.AX vs LDX.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, LDX.AX has a market cap of 167.5M. Regarding current trading prices, MAP.AX is priced at A$0.07, while LDX.AX trades at A$0.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas LDX.AX's P/E ratio is -10.50. In terms of profitability, MAP.AX's ROE is -0.63%, compared to LDX.AX's ROE of -1.64%. Regarding short-term risk, MAP.AX is less volatile compared to LDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check LDX.AX's competition here
MAP.AX vs PEB.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, PEB.AX has a market cap of 148.2M. Regarding current trading prices, MAP.AX is priced at A$0.07, while PEB.AX trades at A$0.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas PEB.AX's P/E ratio is -4.83. In terms of profitability, MAP.AX's ROE is -0.63%, compared to PEB.AX's ROE of -1.31%. Regarding short-term risk, MAP.AX is more volatile compared to PEB.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check PEB.AX's competition here
MAP.AX vs RHY.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, RHY.AX has a market cap of 62.7M. Regarding current trading prices, MAP.AX is priced at A$0.07, while RHY.AX trades at A$0.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas RHY.AX's P/E ratio is -9.50. In terms of profitability, MAP.AX's ROE is -0.63%, compared to RHY.AX's ROE of -4.76%. Regarding short-term risk, MAP.AX is less volatile compared to RHY.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check RHY.AX's competition here
MAP.AX vs CTE.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, CTE.AX has a market cap of 53.4M. Regarding current trading prices, MAP.AX is priced at A$0.07, while CTE.AX trades at A$1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas CTE.AX's P/E ratio is 27.38. In terms of profitability, MAP.AX's ROE is -0.63%, compared to CTE.AX's ROE of +0.73%. Regarding short-term risk, MAP.AX is less volatile compared to CTE.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check CTE.AX's competition here
MAP.AX vs IIQ.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, IIQ.AX has a market cap of 40.3M. Regarding current trading prices, MAP.AX is priced at A$0.07, while IIQ.AX trades at A$0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas IIQ.AX's P/E ratio is -5.75. In terms of profitability, MAP.AX's ROE is -0.63%, compared to IIQ.AX's ROE of -0.37%. Regarding short-term risk, MAP.AX is less volatile compared to IIQ.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check IIQ.AX's competition here
MAP.AX vs BDX.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, BDX.AX has a market cap of 36.5M. Regarding current trading prices, MAP.AX is priced at A$0.07, while BDX.AX trades at A$0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas BDX.AX's P/E ratio is -4.95. In terms of profitability, MAP.AX's ROE is -0.63%, compared to BDX.AX's ROE of -1.64%. Regarding short-term risk, MAP.AX is less volatile compared to BDX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check BDX.AX's competition here
MAP.AX vs GSS.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, GSS.AX has a market cap of 18.2M. Regarding current trading prices, MAP.AX is priced at A$0.07, while GSS.AX trades at A$0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas GSS.AX's P/E ratio is -1.60. In terms of profitability, MAP.AX's ROE is -0.63%, compared to GSS.AX's ROE of -0.24%. Regarding short-term risk, MAP.AX is less volatile compared to GSS.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check GSS.AX's competition here
MAP.AX vs GTG.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, GTG.AX has a market cap of 5.7M. Regarding current trading prices, MAP.AX is priced at A$0.07, while GTG.AX trades at A$0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas GTG.AX's P/E ratio is -3.90. In terms of profitability, MAP.AX's ROE is -0.63%, compared to GTG.AX's ROE of -1.85%. Regarding short-term risk, MAP.AX is more volatile compared to GTG.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check GTG.AX's competition here
MAP.AX vs IBX.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, IBX.AX has a market cap of 4.9M. Regarding current trading prices, MAP.AX is priced at A$0.07, while IBX.AX trades at A$0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas IBX.AX's P/E ratio is -1.10. In terms of profitability, MAP.AX's ROE is -0.63%, compared to IBX.AX's ROE of +1.43%. Regarding short-term risk, MAP.AX is less volatile compared to IBX.AX. This indicates potentially lower risk in terms of short-term price fluctuations for MAP.AX.Check IBX.AX's competition here
MAP.AX vs WFL.AX Comparison April 2026
MAP.AX plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MAP.AX stands at 34.9M. In comparison, WFL.AX has a market cap of 1.5M. Regarding current trading prices, MAP.AX is priced at A$0.07, while WFL.AX trades at A$0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MAP.AX currently has a P/E ratio of -1.70, whereas WFL.AX's P/E ratio is -0.10. In terms of profitability, MAP.AX's ROE is -0.63%, compared to WFL.AX's ROE of +11.65%. Regarding short-term risk, MAP.AX is more volatile compared to WFL.AX. This indicates potentially higher risk in terms of short-term price fluctuations for MAP.AX.Check WFL.AX's competition here